Clinical Trial Search

Primary: Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs) — 231 Participants

Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE) — 30.0; 55.6; 37.5; 14.3 percentage of participants

Primary: Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684 — 675; 792 hour*nanogram per milliliter…

Primary: Percent of Participants With Pregnancy Risk — 11.8; 11.1; 10.2; 10.8 percentage of participants — p=0.6430

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF) — -6.1; -4.3; -2.5; -7.1 units on a scale — p=0.149

Primary: Number of Fitting Modifications to Optimize Vision — 0.21 Lens

Primary: Pharmacokinetics: Observed Maximum Concentration (Cmax) of Insulin Peglispro — 3720 picomoles/liter (pmol/L)

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint — -28.4 units on a scale

Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684 — 509; 786 nanogram*hour/milliliter (ng*h/mL)

Primary: Percentage of Participants With Favorable Overall Response (FOR) — 71.4; 70.0 Percentage of Participants

Primary: GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 8 After Treatment — 86.2; 86.7 percentage improved subjects

Primary: Percentage of Participant With Response at Week 16 — 59 percentage of patients

Primary: The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment — 69.6; 81.1; 75.1 percentage of Participants — p=0.00000241

Primary: Rate of Achieving Targeted Area Under the Curve (AUC) — 5; 3 Participants

Primary: Change From Baseline in A1C at 3 Months — -0.6 percent